Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety Study of Tenapanor in Pediatric Patients With IBS-C
NCT05905926Phase 3Enrolling by invitation
- Sponsor
- Ardelyx
- Start
- Feb 2023
- Primary completion
- Jul 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tenapanor in irritable bowel syndrome (IBS), sponsored by Ardelyx. Primary endpoints: Adverse Events at 40 weeks and Electrocardiogram at 40 weeks. Started Feb 2023; status: enrolling by invitation.
02
Drugs
tenapanor
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT05905926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05905926.